Advertisement

The Epidemiology of Variant Creutzfeldt-Jakob Disease

  • P. G. Smith
  • S. N. Cousens
  • J. N. Huillard d’Aignaux
  • H. J. T. Ward
  • R. G. Will
Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 284)

Abstract

Variant Creutzfeldt-Jakob disease (vCJD) was identified as a new disease in 1996. It was linked to infection with the bovine spongiform encephalopathy (BSE) agent although the epidemiological evidence for this was not strong, but later strain typing studies confirmed the association. The disease has affected predominantly young adults whose dietary and other characteristics are unexceptional compared to control groups, other than that all patients to date have been methoinine homozygous at codon 129 of the prion protein gene and the incidence has been about two times higher in the North of the UK. The number of cases in the 7 years after first identification of the disease has been considerably lower than initially feared, given the likely widespread exposure of the UK population to the BSE agent through contaminated beef products. Predictions of the possible future course of the epidemic have many associated uncertainties, but current mathematical models suggest that more than a few thousand cases is unlikely. Such modelling is limited by the absence of a test for infection with the vCJD agent. The development of a test that could be used on easily accessible tissue to detect infection early in the incubation period would not only advance understanding of the epidemiology of infection with the agent but would also aid the implementation of control measures to prevent potential iatrogenic spread.

Keywords

Bovine Spongiform Encephalopathy Transmissible Spongiform Encephalopathy Bovine Spongiform Encephalopathy Case Average Incubation Period Bovine Spongiform Encephalopathy Agent 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Almond J, Pattison J. Human BSE. Nature 1997; 389: 437–438PubMedCrossRefGoogle Scholar
  2. Alperovitch A, Will RG. Predicting the size of the vCJD epidemic in France. C.R.Acad. Sci III Biologies 2002; 325: 33–36CrossRefGoogle Scholar
  3. Alperovitch A, Zerr I, Pocchiari M, Mitrova E, de Pedro Cuesta J, Hegyi I et al. Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease. Lancet 1999; 353: 1673–1674PubMedCrossRefGoogle Scholar
  4. Anderson RM, Donnelly CA, Ferguson NM, Woolhouse MEJ, Watt CI, Udy HJ et al. Transmission dynamics and epidemiology of BSE in British cattle. Nature 1996; 382: 779–788PubMedCrossRefGoogle Scholar
  5. Andrews NJ, Farrington CP, Cousens SN, Smith PG, Ward HJT, Knight RS et al. Inci- dence of variant Creutzfeldt-Jakob disease in the UK. Lancet 2000; 356: 481–482PubMedCrossRefGoogle Scholar
  6. Andrews NJ, Farrington CP, Ward HIT, Cousens SN, Smith PG, Molesworth AM et al. Deaths from variant Creutzfeldt-Jakob disease in the UK. Lancet 2003; 361: 75 1752Google Scholar
  7. Asante EA, Linehan JM, Desbruslais M, Joiner S, Gowland I, Wood AL et al. BSE prions propagate as either variant CJD-like or sporadic CJD-like prion strains in transgenic mice expressing human prion protein. EMBO J 2002; 21: 6358–6366PubMedCrossRefGoogle Scholar
  8. Bateman D, Hilton D, Love S, Zeidler M, Beck J, Collinge J. Sporadic CreutzfeldtJakob disease in a 18-year-old in the UK. Lancet 1995; 346: 1155–1156PubMedCrossRefGoogle Scholar
  9. Britton TC, al-Sarraj S, Shaw C, Campbell T, Collinge J. Sporadic Creutzfeldt-Jakob disease in a 16-year-old in the UK. Lancet 1995; 346: 1155PubMedCrossRefGoogle Scholar
  10. Brown P, Preece M, Brandel JP, Sato T, McShane L, Zerr I et al. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 2000; 55: 1075–1081PubMedCrossRefGoogle Scholar
  11. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D, Suttie A et al. Transmissions to mice indicate that `new variant’ CJD is caused by the BSE agent. Nature 1997; 389: 498–501PubMedCrossRefGoogle Scholar
  12. Bryant G, Monk PN. Final report of the investigation into the North Leicestershire cluster of variant Creutzfeldt-Jakob., http://www.leics-ha.org.uk/Publics/vcjd_rep. doc, 2001Google Scholar
  13. Cooper JD, Bird SM. UK dietary exposure to BSE in beef mechanically recovered meat: by birth cohort and gender. J Cancer Epidemiol Prevent 2002; 7: 59–70CrossRefGoogle Scholar
  14. Cousens S, Smith PG, Ward H, Everington D, Knight RSG, Zeidler M et al. Geographical distribution of variant Creutzfeldt-Jakob disease in Great Britain, 1994–2000. Lancet 2001; 357: 1002–1007PubMedCrossRefGoogle Scholar
  15. Cousens SN, Linsell L, Smith PG, Chandrakumar M, Wilesmith JW, Knight RSG et al. Geographical distribution of variant CJD in the UK (excluding Northern Ireland). Lancet 1999; 353: 18–21PubMedCrossRefGoogle Scholar
  16. Cousens SN, Vynnycky E, Zeidler M, Will RG, Smith PG. Predicting the CJD epidemic. Nature 1997a; 385: 197–198PubMedCrossRefGoogle Scholar
  17. Cousens SN, Zeidler M, Esmonde TF, DeSilva R, Wilesmith JW, Smith PG et al. Sporadic Creutzfeldt-Jakob disease in the United Kingdom: analysis of epidemiological surveillance data for 1970–96. Br Med J 1997b; 315: 389–395CrossRefGoogle Scholar
  18. d’Aignaux JH, Costagliola D, Maccario J, de Villemeur TB, Brandel JP, Deslys JP et al. Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France. American Academy of Neurology 1999; 53: 1197–1201CrossRefGoogle Scholar
  19. Ferguson NM, Donnelly CA, Ghani AC, Anderson RM. Predicting the size of the epidemic of new variant Creutzfeldt-Jakob disease. Br Food J 1999; 101: 86–98.CrossRefGoogle Scholar
  20. Ferguson NM, Ghani AC, Donnelly AC, Hagenaars TJ, Anderson RM. Estimating the human health risk from possible BSE infection of the British sheep flock. Nature 2002; 709: 1–5Google Scholar
  21. Gail MH, Brookmeyer R. Methods for projecting course of acquired immunodeficiency syndrome epidemic. J Natl Cancer Inst 1988; 80: 900–911PubMedCrossRefGoogle Scholar
  22. Ghani AC, Ferguson NM, Donnelly CA, Hagenaars TJ, Anderson RM. Estimation of the number of people incubating variant CJD. Lancet 1998; 352: 1353–1354PubMedCrossRefGoogle Scholar
  23. Ghani AC, Donnelly CA, Ferguson NM, Anderson RM. Updated projections of future vCJD deaths in the UK. BMC Infect Dis. 2003 3: 4PubMedCrossRefGoogle Scholar
  24. Glatzel M, Rogivue C, Ghani A, Streffer JR, Amsler L, Aguzzi A. Sharply increasedGoogle Scholar
  25. Creutzfeldt-Jakob disease mortality in Switzerland. Lancet 2002; 360:139–141 Gore SM. Commentary: Age related exposure of patients to the agent of BSE should not be downplayed. Br Med 1 1997; 315: 395–396Google Scholar
  26. Gore SM. More than happenstance: Creutzfeldt-Jakob disease in farmers and young adults. Br Med J 1995; 311: 1416–1418CrossRefGoogle Scholar
  27. Harris-Jones R, Knight R, Will RG, Cousens S, Smith PG, Matthews WB. CreutzfeldtJakob disease in England and Wales 1980–84: a case-control study of potential risk factors. J Neurol, Neurosurg Psychiatr 1988; 51: 1113–1119CrossRefGoogle Scholar
  28. Hill AF, Butterworth RI, Joiner S, Jackson G, Rossor MN, Thomas DK et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet 1999; 353: 183–189PubMedCrossRefGoogle Scholar
  29. Hill AF, Desbruslais M, Joiner S, Sidle KCL, Gowland I, Collinge J. The same prion strain causes vCJD and BSE. Nature 1997; 389: 448–450PubMedCrossRefGoogle Scholar
  30. Hilton DA, Fathers E, Edwards P, Ironside JW, Zajicek J. Prion immunoreactivity in appendix before clinical onset of variant Creutzfeldt-Jakob disease. Lancet 1998; 352: 703–704PubMedCrossRefGoogle Scholar
  31. Hilton DA, Ghani AC, Conyers L, Edwards P, McCardle L, Penney M et al. Accumulation of prion protein in tonsil and appendix: review of tissue samples. Br Med J 2002; 325: 633–634CrossRefGoogle Scholar
  32. Horn G, Bobrow M, Bruce M, Goedert M, McLean A, Webster J. Review of the Origin of BSE: Report to UK Government. 2001 www.defra.gov.uk/animalh/bse/bseorigin. pdfGoogle Scholar
  33. Houston F, Foster JD, Chong A, Hunter N, Bostock CJ. Transmission of BSE by blood transfusion in sheep. Lancet 2000; 356: 999–1000PubMedCrossRefGoogle Scholar
  34. Huillard d’Aignaux J, Costagliola D, Maccario J, Billette de Villemeur T, Brandel JP, Deslys JP et al. Incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France. Neurology 1999; 53: 1197–1201PubMedCrossRefGoogle Scholar
  35. Huillard d’Aignaux JN, Cousens SN, Maccario J, Costagliola D, Alpers MP, Smith PG et al. The incubation period of kuru. Epidemiology 2002; 13: 402–408PubMedCrossRefGoogle Scholar
  36. Huillard d’Aignaux JN, Cousens SN, Smith PG. Predictability of the UK variantGoogle Scholar
  37. Creutzfeldt-Jakob disease epidemic. Science 2001; 294: 1729–1731Google Scholar
  38. Hunter N, Foster JD, Chong A, McCutcheon S, Parnham DW, Eaton S et al. Transmission of prion diseases by blood transfusion. J Gen Virol 2002; 83: 2897–2905PubMedGoogle Scholar
  39. Jackson GS, Beck JA, Navarrete C, Brown J, Sutton PM, Contreras M et al. HLA-DQ7 antigen and resistance to variant CJD. Nature 2001; 414: 269–270PubMedCrossRefGoogle Scholar
  40. Kao RR, Gravenor MB, Baylis M, Bostock CJ, Chihota CM, Evans JC et al. The potential size and duration of an epidemic of bovine spongiform encephalopathy in British sheep. Science 2002; 295: 332–335PubMedCrossRefGoogle Scholar
  41. Laplanche JL, Lepage V, Peoc’h K, Delasnerie-Laupretre N, Charron D. HLA in French patients with variant Creutzfeldt-Jakob disease. Lancet 2003; 361: 531–532PubMedCrossRefGoogle Scholar
  42. Lee HS, Brown P, Cervenakova L, Garruto RM, Alpers MP, Gajdusek DC et al. Increased susceptibility to Kuru of carriers of the PRNP 129 methionine/methionine genotype. J Infect Dis 2001; 183: 192–196PubMedCrossRefGoogle Scholar
  43. Liberski PP, Gajdusek DC. Kuru: forty years later, a historical note. Brain Pathol 1997; 7: 555–560PubMedCrossRefGoogle Scholar
  44. Lloyd SE, Onwuazor ON, Beck JA, Mallinson G, Farrall M, Targonski P et al. Identification of multiple quantitative trait loci linked to prion disease incubation period in mice. Proc Natl Acad Sci USA 2001; 98: 6279–6283PubMedCrossRefGoogle Scholar
  45. Lowe J. Evidence of a CJD epidemic may still be missed. Br Med J 2000; 320: 1011CrossRefGoogle Scholar
  46. McLean AR, Bostock CJ. Scrapie infections initiated at varying doses: an analysis of 117 titration experiments. Philos Trans R Soc Lond B Biol Sci 2000; 355: 1043–1050PubMedCrossRefGoogle Scholar
  47. Minor PD, Will RG, Salisbury D. Vaccines and variant CJD. Vaccine 2000; 19:409–410 National CJD Surveillance Unit. Creutzfeldt-Jakob disease surveillance in the UK, http://www.cjd.ed.ac.uk/rep2001.html 2002Google Scholar
  48. Parry HB. Scrapie disease in sheep: historical, clinical, epidemiological and practical aspects of the natural disease. London, Academic Press, 1983Google Scholar
  49. Pepys MB, Bybee A, Booth DR, Bishop MT, Will RG, Little A-M et al. MHC typing in variant Creutzfeldt-Jakob disease. Lancet 2003; 361: 487–489PubMedCrossRefGoogle Scholar
  50. Prusiner SB, Gajdusek DC, Alpers MP. Kuru with Incubation Periods Exceeding Two Decades. Am Neurolog 1982; 12: 1–9CrossRefGoogle Scholar
  51. Sartwell PE. The distribution of incubation periods of infectious disease. Am J Hyg 1950; 51: 310–318PubMedGoogle Scholar
  52. Valleron A-J, Boelle P-Y, Will R, Cesbron J-Y. Estimation of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom. Science 2001; 294: 1726–1728PubMedCrossRefGoogle Scholar
  53. van Duijn CM, Delasnerie-Laupetre N, Masullo C, Zerr I, de Silva R, Wientjens DPWM et al. Case-control study of risk factors of Creutzfeldt-Jakob disease in Europe during 1993–95. Lancet 1998; 351: 1081–1085PubMedCrossRefGoogle Scholar
  54. Verity CM, Nicoll A, Will RG, Devereux G, Stellitano L. Variant Creutzfeldt-Jakob dis- ease in UK children: a national surveillance study. Lancet 2000; 356: 1224–1227PubMedCrossRefGoogle Scholar
  55. Wientjens DPWM, Davanipour Z, Hofman A, Kondo K, Matthews WB, Will RG et al. Risk factors for Creutzfeldt-Jakob disease: a reanalysis of case-control studies. Neurology 1996; 46: 1287–1291PubMedCrossRefGoogle Scholar
  56. Wilesmith JW, Ryan JBM, Hueston WD, Hoinville LJ. Bovine spongiform encephalopathy: epidemiological features 1985–1990. Veterinary Record 1992; 130: 90–94PubMedCrossRefGoogle Scholar
  57. Will RG, Ironside JW, Zeidler M, Cousens SN, Estibeiro K, Alperovitch A et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet 1996; 347: 921–925PubMedCrossRefGoogle Scholar
  58. Will RG, Matthews WB, Smith PG, Hudson C. A retrospective study of CreutzfeldtJakob Disease in England and Wales 1970–1979 II: epidemiology. J Neurol, Neurosurg Psychiatr 1986; 49: 749–755CrossRefGoogle Scholar
  59. Working Party on Bovine Spongiform Encephalopathy. Report of the Working Party on Bovine Spongiform Encephalopathy (Southwood Report). London, UK, Dept of Health and Ministry of Agriculture, Food and Fisheries, 1989Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • P. G. Smith
    • 1
  • S. N. Cousens
    • 1
  • J. N. Huillard d’Aignaux
    • 1
  • H. J. T. Ward
    • 2
  • R. G. Will
    • 2
  1. 1.Department of Infectious and Tropical DiseasesLondon School of Hygiene and Tropical MedicineLondonUK
  2. 2.National CJD Surveillance UnitWestern General HospitalEdinburghUK

Personalised recommendations